10:00 AM EST
Attendees:
Adam Kroetsh (MITRE), Alfred Ouyang (MITRE), Andre Quina (MITRE), Annette Stemhagen (UBC), Becky Metzger (Telligen), Brianna Gallagher, Caitlin Kennedy (CDC), Cathy Graeff (Sonora Advisory Group), Cerdi Beltre (Principia Health Sciences), Cherie Johnson, Chris Funk (UBC), Claudia Manzo (FDA), Daniel Lee (MITRE), David Ostler, Dewey Seto (BMS), Ed Millikan (FDA), George Nayarapally (FDA), James O'Connor (MITRE), Jasmine Roldan (BMS Worldwide Patient Safety), Jennifer Chapman (BMS; Jeremy Jokinen (BMS), Jennifer Church, Jeremy Jokinen, Kal Elhoregy, Keeyan Ghoreshi (MITRE), Kevin Holman, Kim Ball (POCP), Kim Boyd (POCP), Kevin Holman (REMS Industry Consortium), Kyle Irwin (Janssen), Lauren DiCristofaro (MITRE), Linda Pissott Reig, Liza Rodriguez, May Chan-Liston (BMS), Michael Boyce, Michael Cheung (BMS), Dr. Michael Dugan (consultant), Michele Coiro (BMS), Michele Davidson (Walgreens), Mike Menkhaus (Pro Rx Consulting), Miri Alon, Nicole Ng (MITRE), Pooja Babbrah (POCP), Rachel Bonfanti, Rahul Natarajan (TEVA), Richard "Rick" Emery (eviCore), Robert Dingwell (MITRE), Sahil Malhotra (MITRE), Samuel Carter (FDA), Sharon Labbate, Sherice Mills, Stephanie Streib, Steve Bratt (MITRE), Su Chen (MITRE), Violanda Grigorescu, Zachary Robin (MITRE)
Agenda:
- Thank you, Welcome, Logistics of the call - Kim Boyd
- Introductions
- CodeX Overview - Steve Bratt, MITRE - mCODE_CodeX_Intro.pptx
- FDA REMS Perspectives - George Neyarapally, FDA
- Overview REMS Use Case - Kim Boyd
- Attendee open discussion
NOTE: Interested in obtaining additional information on how to become a CodeX Member, championing change in oncology - please reach out to Kim Ball, CodeX Deputy Program Manager, at kim.ball@pocp.com
Problem | Targeted Outcome of CodeX REMS Use Case | Value |
---|---|---|
|
|
|
Brainstorming conversations: Does the use case fill a compelling and urgent need that leads to better, safer, faster care, and lower burden and cost? FDA representatives provided the following details related to their plan: Michele Davidson (Walgreens) mentioned their support and interest of the REMS upstream use case and that the pharmacy SDO ( Critical to have upstream improvement to enhance the transactions and improve automation. If the information is present - then little to know intervention Interaction between the NCPDP Task group and this use case would create greater efficiencies Kevin Holman - Janssen - 60 some odd individual and distinct programs to feed a data pipeline through the EHRs. Independent data bases, independently held within their databases and through their vendors. How will those connections take place? How manufacturers are involved (owned by the individual companies). How would this use case create that connectivity. API (central) Lauren (MITRE) - in order to reduce the number of integrations, difficult with a diverse set of programs. Understand the interfaces is a big part of the process. Kevin - universal API or May (BMS) - In light of the comments on many different sponsors. Is there an example of what success looks like for this? Understanding how we can accomplish from a program and element perspective. What can be established based on particular tasks, in a therapeutic area. Oncology practice - needing and wanting access to all REMS products. How can they have comprehensive access? Lauren - helpful to look at phase descriptions. Piloting new technologies. The phase descriptions found on confluence can be utilized. Mike Menkhaus - Pro Rx - multiple REMS - prescribers cannot know which product the pharmacy is going to dispense, is there appetite for the FDA to create their own REMS administration program and funding based on the own dispensations from each manufacturer. Ed - great comment. Internally well aware of the point Mike made. FHIR standard could open the opportunity for consideration of what Mike is notating. Not agreeing Chat Michael Cheung - To build off what Kevin mentioned regarding the number of individual programs using their own databases, the Sponsors may use different vendors with several different databases which adds to the complexity. I would be interested to understanding how the data would be migrated. Sherice Mills (jazz) - have there been any outreaches discussions with the EHR vendors who already have a framework that can be leveraged. Lauren - yes absolutely. EHRs are using FHIR, within that context can we leverage those existing standards that can be leveraged for the REMS process, enrollment forms for example- certain lab tests detail for example. Starting point. Pooja - great idea - created IGs, NCPDP's eRX specialty enrollment process, we could leverage. As we start digging into this more, what is already created, what are EHRs already doing and can we leverage. Link to Specialty IG: https://build.fhir.org/ig/HL7/fhir-specialty-rx/ Kishore - TEVA - look from multiple use case scenarios - how does the product flow through from the supply chain, from pharmacist how does this use case integrate and harmonize with their workflow. So many stakeholders - how does it integrate with their own current workflows. Kal Elhoregy - alignments among stakeholders - key component for success. Different REMS programs difficult to find alignment. Nicole Ng - community buy-in is key. Reason for convening the codeX REMS case and public engagement. Ed - this is why we are holding the public calls - input - work on this as a whole - community involvement. Jennifer Chapman - When we first had preliminary conversations with prescribers about this topic a few years ago, they had data privacy/security concerns. They feared linking to a manufacturer and worried that we would have access to their non-REMS patients as well.Discovery Session Summary
Themes of Discussion
Barriers/Obstacles
Potential Use Case Starting Points
Next Steps